Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - Cantor Fitzgerald has initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX), a $118 million market cap biotech company, with an Overweight rating. The stock currently trades at $8.95, with analysts setting price targets ranging from $15 to $48.
The research firm highlighted Avalo’s focus on autoimmune diseases, particularly its lead drug candidate AVTX-009, which is an IL-1β antibody currently in clinical development.
AVTX-009 is undergoing a Phase 2 trial for Hidradenitis Suppurativa (HS), which Cantor Fitzgerald describes as a severe skin disease affecting patients.
The Phase 2 trial for Hidradenitis Suppurativa is expected to produce results in mid-2026, according to guidance cited by the research firm.
Avalo Therapeutics is a clinical-stage biotechnology company developing treatments for autoimmune conditions, with its pipeline centered on novel therapeutic approaches.
In other recent news, Avalo Therapeutics has been the focus of several significant developments. Stifel reiterated its Buy rating for the company, maintaining a price target of $36. This decision followed discussions with Avalo’s management team about the selectivity of their lead asset, AVTX-009, in treating Hidradenitis Suppurativa. Additionally, H.C. Wainwright upgraded Avalo Therapeutics to a Buy rating from Neutral, setting a new 12-month price target of $15. This upgrade highlights confidence in Avalo’s strategic direction and potential market performance.
Furthermore, Avalo Therapeutics announced the appointment of Dr. Rita Jain to its Board of Directors. Dr. Jain brings over two decades of leadership experience in biopharmaceutical development, having previously served as Executive Vice President and Chief Medical Officer at ChemoCentryx. Her expertise is expected to support Avalo’s ongoing efforts in developing treatments for immunological diseases. These recent developments indicate a period of strategic growth and potential for Avalo Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.